**PROGRAMMA CONFERENZE FORMATIVE IOSI 2021**

|  |  |  |
| --- | --- | --- |
| **DATA** | **RELATORE** | **TITOLO** |
| 20.01.2021 | **Prof Roger Von Moos**Head of Medical Oncology and Hematology, Kantonsspital Graubünden, Chur (CH)Contatto: Roger.vonMoos@ksgr.ch  | The importance of clinical trials in oncology and barriers to clinical trial participation |
| 24.02.2021 | **Prof. Emanuele Zucca**Vice Head of Oncology Institute of Southern Switzerland (IOSI) and Co-founder of International Extranodal Lymphoma Study Group (IELSG), Bellinzona (CH)Contatto: emanuele.zucca@eoc.ch  | Clinical research in rare entities: practice changing achievements of the IELSG |
| 17.03.2021 | **Prof. Andrea Alimonti**Head Molecular Oncology of Institute of Oncology Research (IOR), Bellinzona (CH)Contatto: andrea.alimonti@ior.usi.ch  | The surprising role of the gut microbiota in prostate cancer progression and therapy |
| 21.04.2021 | **Prof. Miklos Pless**Head of Oncology, Dep of Medical Oncology, Kantonsspital Winterthur (CH)Contatto: miklos.Pless@ksw.ch  | Updates on the treatment of NSCLC |
| 19.05.2021 | **Prof. Robert Coleman**Emeritus Professor of Medical Oncology, University of Sheffield (UK)Contatto: r.e.coleman@sheffield.ac.uk  | Bone health and cancer therapy |
| 16.06.2021 | **Prof. Olivier Michielin**Associate professor of Department of Oncology UNIL CHUV, Lausanne (CH)Contatto: olivier.michielin@unil.ch | Molecular screening of cancer patients: when and how  |
| 15.09.2021 | **Prof. Ruth Plummer**Professor at Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University (UK)Contatto: Ruth.Plummer@newcastle.ac.uk  | DNA repair defects and their targeting in cancer |
| 13.10.2021 | **Prof. George Coukos**Head of Department of Oncology UNIL CHUV and of Immuno-oncology service, Lausanne (CH)Contatto: George.Coukos@chuv.ch  | Update on CAR-T cells and future directions |
| 17.11.2021 | **Prof. John Haanen**Leader Research Theme Immunotherapy, Division of Molecular Oncology & Immunology, Netherlands Cancer Institute (NKI), Amsterdam (NL) Contatto: j.haanen@nki.nl  | New immunotherapy combinations. How to balance toxicity and increased efficacy? |